June 17, 2026

Eight in vivo CAR T biotechs to follow closely

In vivo CAR-T therapies have grown in demand over the years, as scientists have figured out how to crack the challenges of target specificity and safety, proving to be more efficient than ex vivo treatments for cancers and autoimmune conditions.